Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given a consensus recommendation of “Hold” by the eleven brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $31.91.

A number of equities analysts have recently weighed in on the company. Morgan Stanley lowered Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, September 2nd. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. Zacks Research raised Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th.

Smith & Nephew SNATS Trading Down 0.1%

Shares of SNN stock opened at $30.86 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $28.24 and a two-hundred day simple moving average of $29.94. Smith & Nephew SNATS has a 52-week low of $26.12 and a 52-week high of $37.09.

Smith & Nephew SNATS Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be given a dividend of $0.3120 per share. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 236.0%.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Clearstead Trust LLC bought a new stake in Smith & Nephew SNATS in the 2nd quarter valued at $25,000. Addison Advisors LLC purchased a new stake in Smith & Nephew SNATS in the 2nd quarter worth $43,000. Allworth Financial LP purchased a new stake in Smith & Nephew SNATS in the 2nd quarter worth $48,000. Parallel Advisors LLC boosted its holdings in shares of Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares during the last quarter. Finally, Root Financial Partners LLC bought a new position in shares of Smith & Nephew SNATS during the 3rd quarter valued at about $76,000. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.